University College London, UK.
Centre for Cell, Gene and Tissue Therapeutics, Royal Free Hospital, London, UK.
Aesthet Surg J. 2020 Jun 15;40(7):784-799. doi: 10.1093/asj/sjz214.
There is growing interest in the regenerative potential of adipose-derived stem cells (ADSCs) for wound healing applications. ADSCs have been shown to promote revascularization, activate local stem cell niches, reduce oxidative stress, and modulate immune responses. Combined with the fact that they can be harvested in large numbers with minimal donor site morbidity, ADSC products represent promising regenerative cell therapies. This article provides a detailed description of the defining characteristics and therapeutic potential of ADSCs, with a focus on understanding how ADSCs promote tissue regeneration and repair. It summarizes the current regulatory environment governing the use of ADSC products across Europe and the United States and examines how various adipose-derived products conform to the current UK legislative framework. Advice is given to clinicians and researchers on how novel ADSC therapeutics may be developed in accordance with regulatory guidelines.
人们对脂肪来源干细胞(ADSCs)在伤口愈合应用中的再生潜力越来越感兴趣。ADSCs 已被证明可促进再血管化、激活局部干细胞龛、减少氧化应激和调节免疫反应。再加上它们可以大量采集,且供体部位发病率低,ADSC 产品代表了有前途的再生细胞疗法。本文详细描述了 ADSC 的定义特征和治疗潜力,重点是了解 ADSC 如何促进组织再生和修复。它总结了目前管理欧洲和美国 ADCS 产品使用的监管环境,并研究了各种脂肪衍生产品如何符合英国现行立法框架。还向临床医生和研究人员提供了有关如何根据监管指南开发新型 ADSC 疗法的建议。